TABLE 8.
Mode of administration | Immune functiona | Reference(s) |
---|---|---|
In vivo | ||
Mice | ↓↑Cytokine production | 3, 94, 210, 246, 248, 249, 251 |
↓NK activity | 141, 249 | |
↓IgA and IgG production | 249 | |
↑Apoptosis | 61 | |
↓DTH | 245, 246 | |
Rats | ↓TNF-α | 114, 158 |
↓Serum chemokines | 266 | |
↓TNF-α processing | 267 | |
↓Alveolar nitric oxide | 70, 114 | |
↓Chemokines production by Kupffer cells | 17 | |
Humans | ↓Monocyte stimulated proliferation | 232 |
In vitro | ||
Mice | ↓Macrophage killing | 26 |
↑Bactericidal capacity | 263 | |
↓Cytokine production | 41 | |
Humans | ↓Macrophage killing | 26 |
↓↑Cytokine production | 25, 68, 231, 233, 234, 244 | |
↓TNF-α receptor | 25 | |
↓NF-κB activation | 129 | |
↓T-cell proliferation | 232 | |
Rhesus macaques | ↓TNF-α | 226 |
↑, increase; ↓, decrease; ↑↓, both increase and decrease; DTH, delayed-type hypersensitivity.